PLRX

Pliant Therapeutics Inc

0.8589

Oct 30 • 3:59 PM ET -0.0011 (-0.13%)

0.8500

Aftermarket • 6:44 PM ET -0.0089 (-1.04%)

Healthcare Biotechnology USA Micro NASD

Peers: XLO HOWL AGEN BCAX CMPX RCUS SRRK IOVA CADL DYN

| Held by: VTI VXF VHT IWC BUSM BTEC PRFZ

Scroll to Statements

Index	-
Market Cap	53.18M
Enterprise Value	-76.18M
Income	-92.29M
Sales	0.00M
Book/sh	2.37
Cash/sh	2.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	49
IPO	Jun 03, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.36
P/C	0.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.90
Current Ratio	9.90
Debt/Eq	0.20
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	-1.50
EPS next Y	-1.36
EPS next Q	-0.37
EPS this Y	41.07%
EPS next Y	5.16%
EPS next 5Y	23.86%
EPS past 3/5Y	6.05% -15.81%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.84%
Sales Y/Y TTM	-
EPS Q/Q	48.78%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-5.32% -

Insider Own	2.64%
Insider Trans	0.00%
Inst Own	77.35%
Inst Trans	-7.51%
ROA	-37.69%
ROE	-50.29%
ROIC	-53.22%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.25%
SMA50	-17.69%
SMA200	-26.05%
Trades

Shs Outstand	61.92M
Shs Float	60.29M
Short Float	7.69%
Short Ratio	11.70
Short Interest	4.63M
52W High	1.82 -52.68%
52W Low	0.83 3.44%
Volatility	6.02% 5.78%
ATR (14)	0.05
RSI (14)	35.40
Beta	1.34
Rel Volume	0.43
Avg Volume	396.02K
Volume	169,528

Perf Week	-0.54%
Perf Month	-18.20%
Perf Quarter	-17.41%
Perf Half Y	-28.43%
Perf YTD	-29.60%
Perf Year	-47.63%
Perf 3Y	-93.84%
Perf 5Y	-94.61%
Perf 10Y	-
Recom	3.50
Target Price	1.51
Prev Close	0.86
Price	0.86
Change %	-0.13%

Consensus

Sell

Avg. Price Target

$1.51

Implied Upside

+75.8%

Analysts13incl. previous ratings

Rating Distribution2 Buy · 10 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 10, 2025	Downgrade	JJP Morgan	Neutral → Underweight
Mar 04, 2025	Resumed	CCantor Fitzgerald	Neutral
Mar 04, 2025	Downgrade	NNeedham	Buy → Hold
Mar 03, 2025	Downgrade	SStifel	Buy → Hold
Mar 03, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform
Feb 10, 2025	Downgrade	WWells Fargo	Overweight → Equal Weight	$41 → $4	+365.7%
Feb 10, 2025	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$45 → $4	+365.7%
Feb 10, 2025	Downgrade	OOppenheimer	Outperform → Perform
Feb 10, 2025	Downgrade	JJP Morgan	Overweight → Neutral
Feb 10, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Feb 10, 2025	Downgrade	CCitigroup	Buy → Neutral	$40 → $4	+365.7%
Feb 10, 2025	Downgrade	CCanaccord Genuity	Buy → Hold	$43 → $4	+365.7%
Sep 09, 2024	Resumed	LLeerink Partners	Outperform	$46 → $33	+3,742.1%
Dec 08, 2023	Initiated	WWells Fargo	Overweight	$41	+4,673.5%
May 18, 2023	Initiated	CCanaccord Genuity	Buy	$48	+5,488.5%
Apr 13, 2023	Initiated	RRobert W. Baird	Outperform	$44	+5,022.8%
Dec 14, 2022	Initiated	SStifel	Buy	$33	+3,742.1%
Dec 07, 2022	Initiated	JJP Morgan	Overweight	$42	+4,790.0%
Sep 01, 2022	Initiated	CCitigroup	Buy	$36	+4,091.4%
Jul 20, 2022	Initiated	SSVB Leerink	Outperform	$33	+3,742.1%

Mar-01-26 10:39AM	Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference (MarketBeat)
Oct-10-25 09:36AM	Align downgraded, NetEase upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-30-25 07:43AM	Pliant halts bexotegrast development for IPF after trial results (Clinical Trials Arena) -7.20%
Jun-27-25 04:05PM	Pliant Therapeutics Provides Update on BEACON-IPF (GlobeNewswire)
04:03PM	Loading…
May-21-25 04:03PM	Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference (GlobeNewswire)
May-08-25 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-02-25 12:35PM	Pliant cuts workforce by 45% following lung trial termination (Clinical Trials Arena)
07:02AM	Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma (BioPharma Dive)
May-01-25 04:05PM	Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations (GlobeNewswire)
Apr-10-25 12:00PM	PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-07-25 04:05PM	Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference (GlobeNewswire) -6.72%
Apr-03-25 12:22PM	Pliant Therapeutics: An Activist On Deck (Seeking Alpha) -7.09%
Mar-27-25 09:39AM	PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know (Zacks)
Mar-17-25 08:00AM	Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors (GlobeNewswire) +10.39%
07:57AM	Loading…
Mar-14-25 07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
Mar-13-25 07:20AM	Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement (GlobeNewswire)
Mar-04-25 07:23AM	Pliant Therapeutics stock tumbles amid IPF trial cancellation (Clinical Trials Arena)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results (GlobeNewswire) -59.88%
09:27AM	Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Feb-14-25 12:00PM	All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy (Zacks) -7.60%
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive) +20.96%
08:00AM	Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Feb-11-25 09:11AM	Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan (TipRanks) -15.15%
Feb-10-25 01:15PM	Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive (GuruFocus.com) -60.59%
08:32AM	Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues (Benzinga)
Feb-07-25 04:58PM	Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire) -34.81%
Jan-22-25 04:00PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer (GlobeNewswire)
08:00AM	Loading…
Jan-02-25 08:00AM	Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Nov-18-24 06:00PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024 (GlobeNewswire)
Nov-07-24 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	Pliant Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire) +5.37%
Oct-17-24 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting 2024 (GlobeNewswire)
Oct-04-24 09:03PM	Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc (GuruFocus.com)
Oct-01-24 04:35PM	Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs (GlobeNewswire) -5.89%
Sep-30-24 04:45PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-10-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-26-24 09:10AM	Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-07-24 11:53PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 04:03PM	Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-15-24 08:00AM	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures (GlobeNewswire)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-13-24 04:05PM	Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors (GlobeNewswire)
Jun-12-24 04:05PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
May-21-24 06:50PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-14-24 11:28AM	Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial (MT Newswires)
07:30AM	Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-07-24 08:35AM	Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating (MT Newswires)
08:00AM	Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress (GlobeNewswire)
06:59AM	RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk (MT Newswires)
May-06-24 09:55PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) +7.11%
Apr-02-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Mar-27-24 10:23AM	Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference (GlobeNewswire)
Mar-12-24 07:30AM	Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-07-24 10:00AM	Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline (Zacks)
Feb-27-24 04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-07-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Feb-04-24 03:29PM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Jan-19-24 08:28PM	Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares (GuruFocus.com) +5.57%
Jan-03-24 08:00AM	Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 04:30PM	Pliant Therapeutics Presentations at The Liver Meeting 2023 Highlight Bexotegrast, an Inhibitor of v 6 and v 1 Integrins, in Primary Sclerosing Cholangitis (GlobeNewswire) -7.09%
Nov-09-23 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire) -5.52%
08:44AM	Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season? (Zacks)
Nov-08-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 10:00AM	Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Nov-06-23 08:00AM	Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins v 8 and v 1 (GlobeNewswire)
Oct-31-23 04:03PM	Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) +5.16%
Oct-19-23 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer (GlobeNewswire)
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 10:52AM	Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study (Zacks)
09:01AM	Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com) +14.33%
12:10PM	Why Shares of Pliant Therapeutics Are Rising Tuesday (Motley Fool)
07:30AM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Sep-25-23 04:05PM	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis (GlobeNewswire)
Sep-15-23 08:00AM	Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer (GlobeNewswire)
Sep-11-23 08:00AM	Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
Aug-30-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 04:05PM	Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-09-23 05:15PM	Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-25-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-23-23 07:30AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
Jun-05-23 08:02PM	Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks (TipRanks)
06:19AM	Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of 253% over the past year (Simply Wall St.)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cummings Keith Lamont	Chief Financial Officer	Jan 20 '26	Sale	1.28	24,002	30,723	297,214	Jan 22 09:46 PM
Cheung Lily	Chief Human Resource Officer	Jan 20 '26	Sale	1.28	7,534	9,644	44,847	Jan 22 09:38 PM
Coulie Bernard	President and CEO	Jan 20 '26	Sale	1.28	89,375	114,400	505,601	Jan 22 09:38 PM
Kuo Minnie	Chief Operating Officer	Jan 20 '26	Sale	1.28	6,917	8,854	37,806	Jan 22 09:38 PM

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

M.D.Dr. Bernard Jozef Coulie M.B.A.

M.D.Dr. Keith Lamont Cummings M.B.A.

Chief Operating OfficerMs. Minnie Kuo

Scientific Founder & Member of Scientific Advisory BoardDr. Rik Derynck Ph.D.

Scientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLRX

Pliant Therapeutics Inc

Upgrade your Finviz experience